Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Alector
ALEC
Alector
Overvaluation Will Deflate Prospects In A Niche Neurology Market
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
12 Aug 25
Updated
12 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.00
125.0% overvalued
intrinsic discount
12 Aug
US$2.25
Loading
1Y
-56.2%
7D
4.7%
Author's Valuation
US$1.0
125.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.0
125.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-212m
301m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$14.8m
Earnings US$2.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
43.67%
Biotech revenue growth rate
13.35%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.88%
Calculation
US$2.10m
Earnings '28
x
65.76x
PE Ratio '28
=
US$138.02m
Market Cap '28
US$138.02m
Market Cap '28
/
113.84m
No. shares '28
=
US$1.21
Share Price '28
US$1.21
Share Price '28
Discounted to 2025 @ 6.90% p.a.
=
US$0.99
Fair Value '25
